• Product NameOprozomib (ONX 0912)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityOprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.
• Target NameProteasome inhibitor
• CAS No. 935888-69-0
• Calculated MW 532.61
• Formulation C25H32N4O7S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C
  Pathways:Proteases/Proteasome; Ubiquitination
  Receptor:20S proteasome; 20S proteasome
  Boling pt:
  Melting pt:
  Solubility:DMSO: 100 mg/mL (187.75 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Zhou HJ, et al. J Med Chem, 2009, 52(9), 3028-3038.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting